Nexalin Clears Nasdaq Bid-Price Test, Equity Deadline Remains
Nasdaq confirmed the company met its minimum bid-price rule, but Nexalin still faces a $2.5 million equity test by January 4.
Makkler Newsroom · Oct 8, 04:04 PM · 1 min read
Market open· · AUD · Data may be delayed
Avg. target AUD 2.94 (+78.6%)
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO